RANDOMIZED, PARTIAL BLIND STUDY OF THE PHARMACODYNAMICS, PHARMACOKINETICS AND SAFETY OF MULTIPLE SUBCUTANEOUS DOSES OF ALIROCUMAB, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9, ADMINISTERED EVERY 4 WEEKS ALONE OR IN COMBINATION WITH EZETIMIBE OR FENOFIBRATE IN HEALTHY SUBJECTS

✍ Scribed by Rey, Jacques; Poitiers, Franck; Paehler, Tobias; Brunet, Aurelie; Pinquier, Jean-Louis; Hanotin, Corinne; Sasiela, Bill

• Book ID: 121840006
• Publisher: Elsevier Science
• Year: 2014
• Tongue: English
• Weight: 180 KB
• Volume: 63
• Category: Article
• ISSN: 1558-3597
• DOI: 10.1016/S0735-1097(14)61375-9